Bristol Myers Squibb (BMS) continues to describe Seattle and Bothell as important locations for its cancer immunology and cell-therapy work. But the headline figures about regional employees and open jobs come from a December 2021 interview, not a current workforce report. The interview with BMS executive Teresa Foy also offers a snapshot of why the company stayed in Seattle and the immune-cell research directions it was pursuing.
What the 2021 interview reported about BMS in Seattle
In a December 28, 2021 GeekWire interview, Foy said BMS had more than 1,240 employees in the Seattle region and more than 150 regional positions open. Those numbers describe that 2021 snapshot; they should not be read as current headcount or hiring figures.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Cancer Research and textbook 2 | $150.00 | Buy on Amazon |
| 2 |
|
Cancer Chemotherapy, Immunotherapy, and Biotherapy | $244.83 | Buy on Amazon |
| 3 |
|
Nanomedicine and Cancer Research And Textbook 5 | $50.00 | Buy on Amazon |
| 4 |
|
Operative Standards for Cancer Surgery: Volume 3: Sarcoma, Adrenal, Neuroendocrine, Peritoneal... | $116.99 | Buy on Amazon |
| 5 |
|
Holland-Frei Cancer Medicine | $295.24 | Buy on Amazon |
The article described a 266,000-square-foot Seattle research-and-development facility built by Juno and a Bothell manufacturing facility where BMS made Breyanzi. It also cited a $9.2 billion annual research-and-development budget. That was a companywide figure reported in the Seattle story, not spending allocated to Seattle, and it is not a current budget figure.
BMS’s current Washington locations page still describes teams in Seattle and Bothell working to discover, develop, manufacture, and commercialize therapies in cancer immunology and cell therapy. It does not provide a current regional employee count, number of openings, facility area, or Seattle-specific R&D spending.
#1 Best Overall
Why BMS kept a research hub in Seattle
Foy said BMS retained the distributed research model associated with Celgene’s innovation hubs after acquiring Celgene’s Seattle operations. In that model, locations develop areas of specialization and draw on local scientific talent, academic expertise, and smaller biotechnology companies. She emphasized the value of keeping Seattle’s cell-therapy expertise and critical mass in place: “Being able to retain that and grow that here in Seattle is a real strength for us.”
Foy’s remarks about growth were specific to the interview date. She said, “Our presence here is strong,” and, “We’re hiring and we’re growing.” Those quotes are evidence of what she said in 2021, not confirmation of present-day recruitment.
Rank #2
How CAR T therapy uses immune cells
CAR T is a form of cell therapy that uses a patient’s T cells, immune cells that can help recognize and attack abnormal cells. In the general process, cells are collected from the patient, engineered to carry a chimeric antigen receptor (CAR) that recognizes a chosen target, expanded, and returned to the patient. BMS explains the approach and its risks in its cell-therapy overview.
Engineering immune cells does not guarantee that a cancer will respond. CAR T can also trigger inflammatory cytokine release and other toxicities, so managing risk is part of the treatment challenge. This article describes the science and company research, not individual eligibility or treatment advice. The 2021 interview named Breyanzi and Abecma as then-approved CAR T therapies for certain blood cancers; that historical wording is not a current summary of their approvals or who may receive them.
Research directions discussed in the interview
Foy described efforts to improve how engineered cells are made and how long they persist, as well as strategies aimed at cancers that are difficult for immune cells to penetrate or recognize. These are research directions, not established benefits for patients.
Autologous and donor-derived cells
Autologous CAR T begins with a patient’s own cells. Donor-derived, or allogeneic, approaches use cells from another person and are being investigated in hopes of making treatment more readily available and shortening manufacturing waits. BMS’s research-hubs overview describes donor-derived CAR T as investigational and says the approach may shorten manufacturing time. That possibility does not establish that a specific product is available, faster in practice, or appropriate for a given patient.
Cells designed for difficult tumor environments or multiple targets
Foy discussed engineering cells to function in challenging tumor environments and to recognize more than one target. The tumor microenvironment includes cancer cells, immune cells, stromal cells, and connective tissue around a tumor. BMS’s research Q&A notes that this environment can vary by cancer type, genetics, and location, and can be difficult to reproduce outside the body. These features make solid tumors a distinct research challenge; they do not establish that an experimental design works as a treatment.
TCR-engineered cells and immune-cell engagers
The interview also covered T-cell receptor (TCR) engineered cells and immune-cell engagers. TCR approaches alter a T cell’s receptor to recognize cancer-related targets; engagers are designed to bring immune cells into contact with cancer cells. Foy presented these as areas of investigation alongside CAR T, not as proven alternatives or a ranking of treatment options.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Best Value
What the interview said about Seattle’s research ecosystem
Foy described relationships with Fred Hutch and Seattle Children’s Research Institute. She also named Arsenal Bio, Obsidian Therapeutics, and Immatics in discussing next-generation cell-therapy research, and said BMS had discussions with Sana Biotechnology and Lyell Immunopharma. She noted that some programs could compete and that BMS did not then have large collaborations with current local companies.
Those names and relationship descriptions reflect statements in the 2021 interview, not a verified current partner list. The story also mentioned Presage Biosciences, Zymeworks, Silverback Therapeutics, and Lyell in a historical note about investments or Seattle-area operations; it does not establish their present status or relationship with BMS.
What is current—and what remains a dated snapshot
The distinction matters if you are reading the story as a company-growth update. BMS’s current Washington page supports the narrower point that the company continues to identify active Seattle and Bothell work in cancer immunology and cell therapy. It does not substantiate the 2021 headcount, job listings, facility size, budget, or collaboration details as current facts.
The same care applies to the science: research programs are not approved therapies, and a company’s research description is not independent evidence of clinical benefit. Current product indications, patient eligibility, trial stages, hiring, and partner status require up-to-date confirmation from relevant official sources.
Free tools Windows power users keep installed
One-click scans. No signup required.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
